Needham & Company Cuts Price Target on OncoGenex Pharma (OGXI) Following 2Q15
Get Alerts OGXI Hot Sheet
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Needham & Company reiterated a Buy rating on OncoGenex Pharmaceuticals (NASDAQ: OGXI), and cut the price target to $6.00 (from $7.00), following 2Q15. OncoGenex ended the quarter with $60.2 million in cash, and raised an additional $14.7 million through an equity line. Analyst Chad Messer believes the company now has enough cash to last into late 2016, past multiple upcoming milestones.
Messer commented, "OncoGenex ended 2Q:15 with $60.2 million in cash and subsequently raised an additional $14.7 million through an equity line. We believe the company now has enough cash to last into late 2016 past multiple upcoming milestones for both custirsen and apotorsen. Most imminent is the topline readout from poor prognosis subpopulation in the Phase III AFFINITY trial with custirsen in prostate cancer. We have cautious optimism for a positive outcome based on a post-hoc analysis of an earlier failed trial. More importantly, we view OGXI shares as undervalued given the multiple opportunities for near term value creation."
For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.
Shares of OncoGenex Pharmaceuticals closed at $2.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Comcast Corp (CMCSA) PT Lowered to $48 at Pivotal Research
- Meta Platforms Inc. (META) PT Lowered to $575 at UBS, 'shares are offering a 3-to-1 skew'
- Prada SpA (1913:HK) (PRDSY) PT Raised to HK$70 at Macquarie
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!